BioSpace News Archive

– Updated clinical data from BIO89-100 ’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planni ng to initiate the Phase 2b trial as part of the Phase 2b/3 program in NASH in 1H21 – – Topline results from BIO89-100’s Phase 2 SHTG trial expected in 2H21

10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020 Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundatio

Curis, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, a component of the National Institutes of Health, for joint development of CA-4948, a first-in-class small molecule IRAK4 kinase inhibitor, as an anti-cancer agent under the NCI Experimental Therapeutics Program.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ended September 30, 2020 and highlighted recent corporate progress.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million . The company also recorded an additional $750,000 in revenue during the third quarter

--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment-- --MEI Starts Second Fiscal Quarter 2021 with $176.1 Million in Cash--

- Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - - Patient Dosing initiated in Phase 1a/1b trial of anti-VISTA monoclonal antibody, CI-8993, in advanced refractory solid tumors - - Initiation planned for Phase 1 trial of CA-4948 in combination with ibrutinib in NHL -

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference: Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. EST / 6:10 p.m. GMT . Daniel Swisher , president and chief operating officer, w

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthc

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference, a fully virtual management access conference, taking place November 16-18. President and Chief Executive Officer, Mark Foley, is scheduled to participate in a virtual fireside chat on Tuesday, N